There’s a new owner for Brooklyn Park-based Biotest Laboratories and its 75,560 square-foot lab and manufacturing facility. Biotest, which makes sterilization and testing products for the health care ...

Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child 14.12.2021 / 07:00 The issuer is solely ...

Biotest, a subsidiary of Grifols, announced that the US FDA granted approval for its plasma protein therapy Yimmugo earlier today (17 June). Yimmugo is an intravenous immunoglobulin therapy developed ...

eieich, March 31, 2025: Biotest AG (ISIN DE0005227201, ISIN DE0005227235) has today concluded a delisting agreement with its major shareholder, Grifols, S.A., which holds approximately 97.14 % of the ...

Dreieich, 19 September 2025. Biotest AG announces that, after careful consideration, the Management Board has deemed admissible the request received in writing from Grifols S.A. on 1 August 2025 ...

Biotest AG: Biotest accelerates trimodulin development in hospitalized COVID-19 patients with federal funding in the volume of 29 million EUR 23.11.2021 / 15:34 The issuer is solely responsible for ...

If you’re eyeing Biotest and wondering whether now is the right moment to buy, hold, or move on, you’re in good company. The stock has been resting at €28.4, and though its short-term moves have been ...

ROCKAWAY, N.J., Aug. 18 Biotest Diagnostics Corporation(Biotest) -- the U.S. subsidiary of German-based Biotest AG, a worldwidesupplier of traditional and automated blood bank solutions -- announces ...

This document is not, and should not be regarded asinvestment advice or a recommendation, regarding any particular investment. As at the date of publication, the author has a long or short position in ...

BT-061 in clinical development for the treatment of RA and psoriasis ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott and Biotest AG today announced a global agreement to ...

FRANKFURT (Reuters) - Chinese investor Creat Group Corp has offered to buy German blood plasma products maker Biotest (BIOG.DE) for about 1.2 billion euros ($1.3 billion) including debt following its ...

ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the ...